In vivo tracking of stem cells for clinical trials in cardiovascular disease
John V Frangioni1, Roger J Hajjar
1Division of Hematology/Oncology, Department of Radiology, and Molecular Imaging Center, Beth Israel Deaconess Medical Center, 330 Brookline Ave, SL-B05, Boston, Mass 02215, USA. jfrangio@bidmc.harvard.edu
Insights
Tracking stem cells in vivo for cardiovascular disease trials is challenging. Current methods are insufficient, necessitating development of ideal imaging technologies for long-term monitoring of cell location and number.
Area of Science:
- Regenerative Medicine
- Cardiovascular Research
- Medical Imaging
Background:
- Stem cell therapy shows potential for treating cardiovascular diseases.
- Accurate in vivo tracking of stem cells is crucial for clinical trial success.
- Current methods for tracking small cell numbers over time are inadequate.
Purpose of the Study:
- To review existing contrast agents and detectors for stem cell tracking in clinical trials.
- To define the ideal characteristics of an in vivo stem cell imaging technology.
- To propose future research directions for optimal stem cell tracking.
Main Methods:
- Comprehensive literature review of proposed contrast agents and detection systems.
- Analysis of imaging technologies based on requirements for clinical stem cell tracking.
- Identification of gaps and limitations in current stem cell tracking approaches.
Main Results:
- Numerous contrast agents and detectors have been explored for stem cell tracking.
- No single optimal solution currently exists for tracking small cell populations in vivo.
- Key characteristics for an ideal stem cell imaging technology were defined.
Conclusions:
- Effective in vivo stem cell tracking is essential for advancing cardiovascular regenerative medicine.
- Further research and development are needed to create optimal imaging solutions.
- Future efforts should focus on creating technologies that enable precise, long-term monitoring of stem cells.
Abstract:
Various stem cells hold promise for the treatment of human cardiovascular disease. Regardless of stem cell origin, future clinical trials will require that the location and number of such cells be tracked in vivo, over long periods of time. The problem of tracking small numbers of cells in the body is a difficult one, and an optimal solution does not yet exist. We review the many contrast agents and detectors that have been proposed for stem cell tracking during clinical trials, define the characteristics of an ideal imaging technology, and suggest future directions for research.
More Related Videos
12:54In Vivo 4-Dimensional Tracking of Hematopoietic Stem and Progenitor Cells in Adult Mouse Calvarial Bone Marrow
Published on: September 4, 2014
07:31In Vivo Tracking of Human Adipose-derived Mesenchymal Stem Cells in a Rat Knee Osteoarthritis Model with Fluorescent Lipophilic Membrane Dye
Published on: October 8, 2017
